Akums Delivers Strong Q3 FY26 Performance with 14.8% Revenue Growth and 21% Adj EBITDA Growth
Feb 14, 2026
New Delhi [India], February 14: Akums Drugs & Pharmaceuticals Ltd., India's Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the third quarter of FY26.
Read More...